Tumour-absorbed dose and efficacy of peptide receptor radionuclide therapy with [90Y]Y-DOTATOC in patients with refractory meningioma: a single-centre experience
5 affiliations
- 1Department of Nuclear Medicine, Medical University of Innsbruck, Anichstr. 35, Innsbruck, 6020 Austria
- 2Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
- 3Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria
- 4Neuroimaging Core Facility, Medical University of Innsbruck, Innsbruck, Austria
- 5Department of Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria
Abstract
Aim:: The management of treatment-refractory meningioma in patients with previous surgical resection and radiation therapy remains challenging due to the lack of effective systemic treatment options. Therefore, novel therapeutic applications, such as peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors, may offer a promising therapeutic strategy. We aimed to assess the lesion-based tumour-absorbed dose and efficacy of PRRT with [90Y]Y-DOTATOC in patients with treatment-refractory meningioma.
Materials and methods:: In this study, 10 patients with therapy-refractory meningioma were retrospectively included. All patients received systemic [90Y]Y-DOTATOC therapy following prior surgical resection and radiation therapy. In total, 21 lesions were assessed morphologically by contrast-enhanced MRI and [68Ga]Ga-DOTATOC PET/CT both before and after therapy. All patients underwent dosimetry with [111In]In-DOTATOC prior to [90Y]Y-DOTATOC therapy. Treatment response was evaluated according to RANO bidimensional and volumetric criteria. Overall survival (OS) was defined from the first PRRT cycle until death.
Results:: The median cumulative activity administered per patient was 3804 MBq (IQR, 3140–4050 MBq), with a median of 3 cycles (range: 1–7). On lesion-based analysis following PRRT, response assessment was available in 19/21 (91.5%) lesions. Among these, tumour stabilisation according to RANO criteria was observed in 7/19 (36.8%) lesions, with a median cumulative tumour-absorbed dose of 52.7 Gy. Morphological tumour progression was noted in 12/19 (63.2%) lesions, with a median cumulative tumour-absorbed dose of 43.8 Gy. The difference in tumour-absorbed doses between morphologically stable and progressive lesions according to RANO criteria was not statistically significant (P = 0.82). Values for SUVmax and SUVmean from pretherapeutic [68Ga]Ga-DOTATOC PET/CT significantly correlated with the tumour-absorbed doses (P = 0.018 for SUVmax, P = 0.021 for SUVmean, respectively). Post-therapeutic [68Ga]Ga-DOTATOC PET/CT demonstrated an increase in SUVmax in 19/21 (90.5%) lesions (median: 40.8%, range: 13.0% − 101.2%). The median OS in the whole cohort was 23.0 months (95% CI 12.5–33.5 months).
Conclusion:: Our preliminary results indicate no significant difference in tumour-absorbed doses between morphologically stable lesions and those with progressive disease, as defined by the RANO criteria. However, lesion-based analysis revealed a significant correlation between pretherapeutic [68Ga]Ga-DOTATOC PET/CT uptake and tumour-absorbed doses following [90Y]Y-DOTATOC therapy. These findings suggest that baseline PET/CT may serve as a valuable tool for estimating cumulative tumour-absorbed dose and guiding the optimal cumulative activity of PRRT.
Related
- Efficacy and safety of ultrasound-guided microwave “Near-Total Ablation” for refractory hyperthyroidism: a retrospective study
- Efficacy and safety of P2X3 receptor antagonists in refractory or unexplained chronic cough: an updated systematic review and meta-analysis
- Striking leflunomide efficacy against refractory cutaneous sarcoidosis
- 1187 Safety and efficacy of cesalatamig, a novel PD-1/VEGF bispecific antibody, as monotherapy in PD-(L)1–resistant/refractory NSCLC: Results from global, multicenter, open-label phase 1/2 studies
- Efficacy analysis and adverse event management of selinexor in the treatment of relapsed/refractory multiple myeloma.
BibTeX
@article{schweiger2026tumourabsorbed,
title = {{Tumour-absorbed dose and efficacy of peptide receptor radionuclide therapy with [90Y]Y-DOTATOC in patients with refractory meningioma: a single-centre experience}},
author = {Lilit Schweiger and Giulia Santo and Ariane Kronthaler and Gianpaolo di Santo and Sarah Iglseder and Stephanie Mangesius and Julian Mangesius and Katharina Stock and Irene Virgolini},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
month = aug,
doi = {10.1007/s00259-026-08113-9},
url = {https://doi.org/10.1007/s00259-026-08113-9},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Tumour-absorbed dose and efficacy of peptide receptor radionuclide therapy with [90Y]Y-DOTATOC in patients with refractory meningioma: a single-centre experience
AU - Lilit Schweiger
AU - Giulia Santo
AU - Ariane Kronthaler
AU - Gianpaolo di Santo
AU - Sarah Iglseder
AU - Stephanie Mangesius
AU - Julian Mangesius
AU - Katharina Stock
AU - Irene Virgolini
PY - 2026
DA - 2026/08/05
JO - European Journal of Nuclear Medicine and Molecular Imaging
DO - 10.1007/s00259-026-08113-9
UR - https://doi.org/10.1007/s00259-026-08113-9
AB - Aim:: The management of treatment-refractory meningioma in patients with previous surgical resection and radiation therapy remains challenging due to the lack of effective systemic treatment options. Therefore, novel therapeutic applications, such as peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors, may offer a promising therapeutic strategy. We aimed to assess the lesion-based tumour-absorbed dose and efficacy of PRRT with [90Y]Y-DOTATOC in patients with treatment-refractory meningioma. Materials and methods:: In this study, 10 patients with therapy-refractory meningioma were retrospectively included. All patients received systemic [90Y]Y-DOTATOC therapy following prior surgical resection and radiation therapy. In total, 21 lesions were assessed morphologically by contrast-enhanced MRI and [68Ga]Ga-DOTATOC PET/CT both before and after therapy. All patients underwent dosimetry with [111In]In-DOTATOC prior to [90Y]Y-DOTATOC therapy. Treatment response was evaluated according to RANO bidimensional and volumetric criteria. Overall survival (OS) was defined from the first PRRT cycle until death. Results:: The median cumulative activity administered per patient was 3804 MBq (IQR, 3140–4050 MBq), with a median of 3 cycles (range: 1–7). On lesion-based analysis following PRRT, response assessment was available in 19/21 (91.5%) lesions. Among these, tumour stabilisation according to RANO criteria was observed in 7/19 (36.8%) lesions, with a median cumulative tumour-absorbed dose of 52.7 Gy. Morphological tumour progression was noted in 12/19 (63.2%) lesions, with a median cumulative tumour-absorbed dose of 43.8 Gy. The difference in tumour-absorbed doses between morphologically stable and progressive lesions according to RANO criteria was not statistically significant (P = 0.82). Values for SUVmax and SUVmean from pretherapeutic [68Ga]Ga-DOTATOC PET/CT significantly correlated with the tumour-absorbed doses (P = 0.018 for SUVmax, P = 0.021 for SUVmean, respectively). Post-therapeutic [68Ga]Ga-DOTATOC PET/CT demonstrated an increase in SUVmax in 19/21 (90.5%) lesions (median: 40.8%, range: 13.0% − 101.2%). The median OS in the whole cohort was 23.0 months (95% CI 12.5–33.5 months). Conclusion:: Our preliminary results indicate no significant difference in tumour-absorbed doses between morphologically stable lesions and those with progressive disease, as defined by the RANO criteria. However, lesion-based analysis revealed a significant correlation between pretherapeutic [68Ga]Ga-DOTATOC PET/CT uptake and tumour-absorbed doses following [90Y]Y-DOTATOC therapy. These findings suggest that baseline PET/CT may serve as a valuable tool for estimating cumulative tumour-absorbed dose and guiding the optimal cumulative activity of PRRT.
SN - 1619-7070
SN - 1619-7089
ER -